These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 18433957

  • 21. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
    Sinsakul M, Sika M, Rodby R, Middleton J, Shyr Y, Chen H, Han E, Lehrich R, Clyne S, Schulman G, Harris R, Lewis J.
    Am J Kidney Dis; 2007 Dec; 50(6):946-51. PubMed ID: 18037095
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes.
    Rodríguez-Morán M, Guerrero-Romero F.
    Curr Diabetes Rev; 2008 Feb; 4(1):55-62. PubMed ID: 18220696
    [Abstract] [Full Text] [Related]

  • 23. The renoprotective potential of pentoxifylline in chronic kidney disease.
    Lin SL, Chiang WC, Chen YM, Lai CF, Tsai TJ, Hsieh BS.
    J Chin Med Assoc; 2005 Mar; 68(3):99-105. PubMed ID: 15813241
    [Abstract] [Full Text] [Related]

  • 24. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases.
    Chen YM, Lin SL, Chiang WC, Wu KD, Tsai TJ.
    Kidney Int; 2006 Apr; 69(8):1410-5. PubMed ID: 16541021
    [Abstract] [Full Text] [Related]

  • 25. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
    Navarro JF, Mora C, Muros M, García J.
    J Am Soc Nephrol; 2005 Jul; 16(7):2119-26. PubMed ID: 15917336
    [Abstract] [Full Text] [Related]

  • 26. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK, Dormanesh B, Sagheb MM, Roozbeh J, Vessal G, Pakfetrat M, Daneshbod Y, Kamali-Sarvestani E, Lankarani KB.
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria.
    Badri S, Dashti-Khavidaki S, Lessan-Pezeshki M, Abdollahi M.
    J Pharm Pharm Sci; 2011 Dec; 14(1):128-37. PubMed ID: 21501559
    [Abstract] [Full Text] [Related]

  • 30. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun 28; 349(9069):1857-63. PubMed ID: 9217756
    [Abstract] [Full Text] [Related]

  • 31. Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial.
    de Morales AM, Goicoechea M, Verde E, Carbayo J, Barbieri D, Delgado A, Verdalles U, de Jose AP, Luño J.
    J Nephrol; 2019 Aug 28; 32(4):581-587. PubMed ID: 30949987
    [Abstract] [Full Text] [Related]

  • 32. Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: A systematic review and meta-analysis.
    Leporini C, Pisano A, Russo E, D Arrigo G, de Sarro G, Coppolino G, Bolignano D.
    Pharmacol Res; 2016 May 28; 107():315-332. PubMed ID: 26995301
    [Abstract] [Full Text] [Related]

  • 33. Pentoxifylline in management of proteinuria in diabetic nephropathy.
    Tripathi K, Prakash J, Appaiha D, Srivastava PK.
    Nephron; 1993 May 28; 64(4):641-2. PubMed ID: 8366994
    [No Abstract] [Full Text] [Related]

  • 34. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
    Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ.
    Am J Kidney Dis; 2008 Feb 28; 51(2):199-211. PubMed ID: 18215698
    [Abstract] [Full Text] [Related]

  • 35. Pentoxifylline, total urinary protein excretion rate and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy.
    Solerte SB, Fioravanti M, Patti AL, Schifino N, Zanoletti MG, Inglese V, Ferrari E.
    Acta Diabetol Lat; 1987 Feb 28; 24(3):229-39. PubMed ID: 3687315
    [Abstract] [Full Text] [Related]

  • 36. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases.
    Liou HH, Huang TP, Campese VM.
    Nephron; 1995 Feb 28; 69(1):41-8. PubMed ID: 7891796
    [Abstract] [Full Text] [Related]

  • 37. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U, Chaisuvannarat V.
    J Med Assoc Thai; 2009 May 28; 92(5):611-7. PubMed ID: 19459520
    [Abstract] [Full Text] [Related]

  • 38. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial.
    Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY.
    Am J Kidney Dis; 2012 Jan 28; 59(1):67-74. PubMed ID: 22019331
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial.
    Rodriguez-Morán M, González-González G, Bermúdez-Barba MV, Medina de la Garza CE, Tamez-Pérez HE, Martínez-Martínez FJ, Guerrero-Romero F.
    Clin Nephrol; 2006 Jul 28; 66(1):3-10. PubMed ID: 16878429
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.